212 related articles for article (PubMed ID: 25940377)
1. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Okusaka T; Ueno H; Morizane C; Kondo S; Sakamoto Y; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):628-33. PubMed ID: 25940377
[TBL] [Abstract][Full Text] [Related]
2. Endocrine tumours of the gastrointestinal tract: Chemotherapy.
Arnold R; Rinke A; Schmidt Ch; Hofbauer L
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):649-56. PubMed ID: 16183533
[TBL] [Abstract][Full Text] [Related]
3. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
4. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
Mueller D; Krug S; Majumder M; Rinke A; Gress TM
BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Koumarianou A; Kaltsas G; Kulke MH; Oberg K; Strosberg JR; Spada F; Galdy S; Barberis M; Fumagalli C; Berruti A; Fazio N
Neuroendocrinology; 2015; 101(4):274-88. PubMed ID: 25924937
[TBL] [Abstract][Full Text] [Related]
6. New treatment options with cytotoxic agents in neuroendocrine tumours.
Hammel P; Hentic O; Neuzillet C; Faivre S; Raymond E; Ruszniewski P
Target Oncol; 2012 Sep; 7(3):169-72. PubMed ID: 22911013
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Rashidi A; Sorscher SM
Leuk Lymphoma; 2015; 56(8):2468-9. PubMed ID: 25530344
[No Abstract] [Full Text] [Related]
8. Pancreatic neuroendocrine tumors: does chemotherapy work?
Tejani MA; Saif MW
JOP; 2014 Mar; 15(2):132-4. PubMed ID: 24618436
[TBL] [Abstract][Full Text] [Related]
9. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
11. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Bracht LK; Wen P; Meyerhardt JA; Kulke MH; Hornick JL; Redston M; LaFrankie DC; Black PM; Kesari S; Norden A; Drappatz J
J Clin Oncol; 2008 Oct; 26(29):4843-4. PubMed ID: 18779600
[No Abstract] [Full Text] [Related]
12. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Kulke MH; Hornick JL; Frauenhoffer C; Hooshmand S; Ryan DP; Enzinger PC; Meyerhardt JA; Clark JW; Stuart K; Fuchs CS; Redston MS
Clin Cancer Res; 2009 Jan; 15(1):338-45. PubMed ID: 19118063
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
15. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
Clewemar Antonodimitrakis P; Sundin A; Wassberg C; Granberg D; Skogseid B; Eriksson B
Neuroendocrinology; 2016; 103(3-4):345-53. PubMed ID: 26279284
[TBL] [Abstract][Full Text] [Related]
16. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
[TBL] [Abstract][Full Text] [Related]
17. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Costa FP; Gumz B; Pasche B
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):843-54. PubMed ID: 23582923
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
[TBL] [Abstract][Full Text] [Related]
19. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Strosberg J; Goldman J; Costa F; Pavel M
Front Horm Res; 2015; 44():239-47. PubMed ID: 26303716
[TBL] [Abstract][Full Text] [Related]
20. Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.
Wu YL; Raj N; Reidy-Lagunes D
Pancreas; 2020 Jan; 49(1):e14-e16. PubMed ID: 31856101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
